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During Q4 2012 and Q1 2013, the cell therapy industry made strong progress in translation and commercial-
ization. Continued development of the companies included in a dedicated stock market index suggests
emergence of this industry as a distinct healthcare sector.This Industry Progress update covers
developments for publicly traded cell
therapy companies with market capitali-
zations (market caps) greater than $50M
for the period ranging from October 1,
2012 to March 31, 2013. We discuss
external influencing factors affecting the
industry and significant news from the
companies during the period, and we pre-
sent the stock market activity of their
shares in the form of a dedicated index,
the Cell Therapy Index (CTI), to give an
indication of the financial progress of the
sector overall.
Major External Influences
Federal Funding for Human
Embryonic Stem Cell Research
On January 7, 2013, the US Supreme
Court decided not to hear the appeal of
the case of Sherley versus Sebelius. As
is the custom for the Supreme Court, no
reasonwas given. The origin of the lawsuit
was targeted at the guidelines issued by
the National Institutes for Health (NIH) in
July 2009 implementing President Oba-
ma’s executive order, ‘‘Removing Barriers
to Responsible Scientific Research
Involving Human Stem Cells,’’ which lifted
some of his predecessor’s restrictions on
federal funding for human embryonic
stem cell (hESC) work. Sherley initially
won a preliminary injunction against the
NIH. However, the trial court and later
the appeals court ruled in the NIH’s favor.
The final petition to the Supreme Court
was denied, thus bringing to a close the
3 year legal battle challenging the legality644 Cell Stem Cell 12, June 6, 2013 ª2013 Eof funding hESC research by the NIH
(Baker, 2013). Industry and academia
have welcomed this news because it re-
moves uncertainty about a large pool of
existing and future research.
Patenting of hESCs in Europe
In the case of Oliver Bru¨stle versus Green-
peace, relating to the patentability of
neural precursor cells derived from
hESCs, the Court of Justice of the Euro-
pean Union (CJEU) ruled in late 2011
that, ‘‘a process which involves removal
of a stem cell from a human embryo at
the blastocyst stage, entailing the
destruction of that embryo, cannot be
patented.’’ This ruling created uncertainty
for hESC-based companies and cast a
shadow over the technology with con-
cerns that there might be a much larger
knock-on effect. However, on November
27, 2012 the Bundersgerichtshof, the
German court that had originally referred
the legal questions to the CJEU, applied
the CJEU ruling narrowly, thereby
enabling inventors to be granted patents
over hESC-derived cell technologies
that (1) do not directly involve embryo
destruction (effectively the practice of
the UK Intellectual Property Office) and/
or (2) expressly exclude (‘‘disclaim’’)
destructive uses of human embryos
even if there were no such nondes-
tructive uses at the application date. It
remains to be seen whether other EU
Member States will adopt a similar
approach, but if they do, the impact of
the original CJEU ruling could well be
significantly curtailed.lsevier Inc.UK Cell Therapy Catapult
Fundedwith $110Mof public funds via the
Technology Strategy Board, the Cell
Therapy Catapult has been established
at Guy’s Hospital, London. The Catapult
is focused on bridging the gap between
academic discoveries and the point
where they are investment ready—typi-
cally at the end of a successful phase 2
clinical trial. An internationally respected
senior management team is now in place
and the first corporate deals are starting
to emerge. The initial commercial collabo-
ration is an R&D program with ReNeuron
(Guildford, UK) to work on new manu-
facturing technologies and assays in or-
der to advance ReNeuron’s lead stem
cell therapy (CTX). CTX is already pro-
gressing in a phase 1 trial for stroke and
is also shortly to enter a trial for critical
limb ischemia. The Catapult will
contribute $2M to the collaboration in
the form of expert knowledge, access to
state-of-the art facilities, and equipment.
California Institute for Regenerative
Medicine
In response to the critical review of the
California Institute for Regenerative Med-
icine (CIRM) carried out by the Institute of
Medicine at CIRM’s request, its Govern-
ing Board has proposed a number of
major changes across multiple areas
including increased involvement with
industry. The report, published in
December 2012, acknowledged the
many achievements of CIRM, including
establishing California as an international
hub of stem cell R&D, but also identified
Cell Stem Cell
Industry Progresskey areas for urgent improvement
including the need for an external scienti-
fic advisory board, resolution of the
perceived conflicts of interest on its gov-
erning board, and reorganization to
ensure that the board is able to provide
independent oversight (DeFrancesco,
2013a).
In January 2012, an independent eco-
nomic impact study by the Berkeley
Research Group focusing on the first
$1.5B of CIRM’s grant funding reported
that it ‘‘is generating 38,000 job years
and $286M in new tax revenue in the state
through 2014.’’ However, 13,000 of the
jobs are in the construction and building
trades. The report does not measure the
economic impact of stem-cell-based
companies that have opened facilities
or expanded in the state as a direct result
of CIRM’s activities. The report states that
it is too early to quantify CIRM’s impact on
the traditional biotech clusters (the Bay
Area and San Diego), but notes that, ‘‘in-
dustries participating in a strong cluster
register higher employment growth, as
well as higher wages, number of estab-
lishments, and patenting.’’ An example
given is ViaCyte (San Diego, CA, USA),
who have had a 45%growth in their head-
count to over 50 staff since receiving their
first CIRM grant in 2009.
CTI
Globally there are between 300 and 700
companies actively progressing cell-
based therapies, ranging from small
university spinouts to multinational
companies such as GlaxoSmithKline,
Johnson & Johnson, Pfizer, and Sanofi
(Genzyme). If one excludes the larger
pharmaceutical, biologics, and/or medi-
cal device companies, there are around
50 publicly traded companies of various
different sizes that focus predominantly
on cell-based approaches (Mason et al.,
2012).
In a previous article, we outlined the
application of a bespoke stock index of
cell therapy companies to monitor the
overall growth and volatility of this indus-
try sector (Brindley et al., 2011). To pro-
duce a fair representation of an industry
overall and to damp down excessive vola-
tility, it is conventional to calculate aggre-
gated indices of only the companies with
market caps greater than a value appro-
priate for the specific industry. Given the
very large spread of market caps for celltherapy companies, we selected a cutoff
of $50M for compiling a new CTI. On
October 1, 2012, this cut off resulted in
25 companies being included to form the
CTI. Table S1 shows a list of the com-
panies together with a brief description
of their technologies and regulatory
approved products. Due to the large
range of values for the market caps and
share prices, the market caps are
weighted, and the percentage change in
the closing price of the share each day
compared to the initial price on the start-
ing date is used to calculate the CTI.
Similarly to the situation seen in a previ-
ous analysis (Brindley et al., 2011), indi-
vidual share prices and the index value
overall showed significant variation during
the 6 month period following October 1,
2012. For example, the aggregated mar-
ket cap dropped from over $7B on
October 1, 2012 to approximately $6B
on January 1, 2013, finally recovering to
just over $7B by March 31, 2013. It is of
note that for each of these time points,
Mesoblast was a predominant force,
contributing to one-third of the loss in
Q4 2012 and half of the gain in Q1 2013.
Mesoblast is a bellwether stock in the
sector. The share price falls were due to
rumors about when, and even if, Meso-
blast and its strategic partner, Teva Phar-
maceuticals, would start its phase 3
congestive heart failure trial (which were
proven unfounded in November 2012),
and rumors of a new financing of $180M
that probably negatively impacted the
share price in the months preceding the
March 2013 raise.
The cell therapy industry can be con-
sidered a fourth pillar of therapeutic
healthcare, complementing the medical
device, pharmaceutical, and biotech-
nology sectors (Mason et al., 2011). How-
ever, investors frequently group cell
therapy together with biotechnology, so
we have also plotted two of biotech’s
most trusted indices (NYSE Arca Biotech-
nology Index [BTK] and Nasdaq Biotech-
nology Index [NBI]) alongside the CTI to
enable comparison. It is important to
note the substantial difference in the
maturity of the two industries, i.e., of
fledgling companies with no/little revenue
versus predominantly small and large cap
companies, several with billion dollar rev-
enues. The NBI consists of both biotechs
and pharmaceutical companies. It is
calculated using a modified capitaliza-Cell Stem Cetion-weighted methodology from com-
panies with a market cap of at least
$200M. It covers approximately 120
companies, a few of which focus on cell-
based therapy, such as Cytori Therapeu-
tics, Dendreon, and Osiris Therapeutics
(Thomas, 2012). The BTK is an equal
dollar weighted, concentrated index of
20 large biotechnology stocks and also in-
cludes Dendreon.
During the period from October 1, 2012
to March 31, 2013, the CTI behaved very
differently from the biotech indices
(Figure 1), confirming our earlier observa-
tion that the cell therapy sector is a unique
and distinct investment class relative to
biotech (Brindley et al., 2011). During Q4
2012 the CTI lost around 20% of its value
and then proceeded to a near-full recov-
ery. For the same period, the BTK and
NBI also initially lost value early on, but
recovered earlier and underwent steady
growth from November 2012 onward.
The major gains in the NBI and BTK are
seen as an extension of the investor con-
fidence in the biotech sector seen virtually
throughout 2012. Highlights for the period
included eight new drugs being approved
for marketing by the FDA in December,
bumping the total number of drug ap-
provals for the calendar year to 37, the
largest number of approvals since 1996
(Osborne, 2013). This momentum has
continued: within a couple of months of
the start of 2013, six further drugs had
received FDA approval (DeFrancesco,
2013b). The biotech indices also outper-
formed the general markets last year, as
investors enthusiastically accumulated
shares in the larger market cap com-
panies, including Amgen, Biogen Idec,
and Gilead Sciences, the three of which
produced close to $60B in combined
shareholder gains during 2012 (Yang,
2013).
News for Companies in the CTI
Aastrom Biosciences, in response to
financial constraints, made a strategic
shift to focus solely on their phase 2b ix-
myelocel-T trial for dilated cardiomyopa-
thy and to stop the phase 3 critical limb
ischemia study.
Advanced Cell Technology’s indepen-
dent Data and Safety Monitoring Board,
which oversees the clinical trials in the
US and EU for Stargardt’s macular dys-
trophy and dry age-related macular
degeneration, has authorized an increasell 12, June 6, 2013 ª2013 Elsevier Inc. 645
Figure 1. Cell Therapy Index for Q4 2012 and Q1 2013
The index is composed of cell therapy companies with market capitalizations greater than $50M. It com-
mences on October 1, 2012 with a benchmark value set at 1,000. The major established biotechnology
indices (BTK and NBI) are included and demonstrate that the cell therapy industry is a unique investment
class and thus distinct from biotech. See also Table S1.
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150,000 hESC-derived retinal pigment
epithelial cells.
Athersys was named for a second year
in Deloitte’s Technology Fast 500, a
ranking of the 500 fastest growing tech-
nology, media, telecommunications, life
sciences, and clean technology com-
panies in North America. Athersys’ reve-
nues grew 217% during the year.
Bionet’s data for 2011 shows sales rev-
enues of $20M, of which 94% was from
cord blood banking operations. Bionet
subsidiary Genesis Genetics Asia made
its initial public offering on the Gre Tai
Securities Market (Taiwan). This is the
country’s first publicly traded company
specialized in providing genetic testing,
databases, and informatics services to
the life sciences industry.
BioTime subsidiary Asterias
Biotherapeutics (formerly BioTime
Acquisition Corporation, Menlo Park,
CA, USA) agreed to acquire Geron’s
(CA, USA) hESC programs including intel-
lectual property, cell lines, and a phase 1
clinical trial for spinal cord injury, in ex-
change for $5Mcash, 9MBioTime shares,
and warrants. Geron will be entitled to
royalties on future commercial products.
China Cord Blood Corporation (CCBC),
China’s largest cord blood bank, was
granted American Association of Blood646 Cell Stem Cell 12, June 6, 2013 ª2013 EBanks (AABB) Accreditation for its Beijing
subsidiary. AABB is an international, not-
for-profit association dedicated to the
advancement of science and the practice
of blood centers and transfusion medi-
cine. It is committed to developing and
delivering standards, accreditation, and
educational programs.
Cordlife Group and CCBC have formed
a strategic partnership. As a result, CCBC
nowwholly ownsGuangzhouMunicipality
Tianhe Nuoya Bio-engineering Company,
a cord blood banking operator in Guang-
dong (Canton) province, in exchange for
10% of CCBC.
Cytomedix will collaborate with the NIH
on a phase 2 trial for intermittent leg clau-
dication. Funded by NHLBI/NIH and
managed by the Cardiovascular Cell
Therapy Research Network (consisting
of seven US centers), the study is an 80
patient, double-blind, placebo-controlled
trial intended to demonstrate the safety
and efficacy of Cytomedix’s ALD-301
cells.
Cytori Therapeutics lost its appeal to
the US Court of Appeals regarding the
FDA’s decision that the Celution cell pro-
cessing technology was not substantially
equivalent to the cited predicate devices
required for 510(k) approval. Cytori will
instead seek regulatory approval via the
Premarket Approval (PMA) route with car-lsevier Inc.diac disease trials that are already
underway.
Dendreon sold its immunotherapy
manufacturing facility at Morris Plains
(NJ, USA) to Novartis for $43M. The
173,000 square foot state-of-the-art cell
processing facility was built for
manufacturing Provenge (sipuleucel-T).
Dendreon had already announced its
intent to wind down Morris Plains as part
of a restructuring plan.
Fibrocell Science’s phase 2 study to
evaluate the safety and efficacy of LaViv
(azficel-T) for the treatment of moderate-
to-severe acne scars has been accepted
for publication in Dermatologic Surgery.
LaViv therapy was associated with clini-
cally meaningful improvement in acne
scar appearance and was judged safe
and superior to control treatment.
ImmunoCellular Therapeutics had its
investigational new drug (IND) application
allowed by the FDA for ICT-140, a
dendritic cell vaccine targeting seven an-
tigens that are overexpressed in ovarian
cancer and cancer stem cells. This safety
study will enroll approximately 20 patients
who have previously been treated with
standard chemotherapy.
Japan Tissue Engineering Company
(J-TEC) is now reimbursed for JACC
(autologous cultured cartilage) for trau-
matic knee cartilage deficiency and os-
teochondritis dissecans from Japan’s
medical insurance system. Osteoarthritis
was excluded from the indications. The
insurance-reimbursed price is U2M
($21,000) including tax. JACC received
Japanese regulatory approval (Ministry
of Health, Labour and Welfare) in 2012.
Medipost started a phase 1/2a trial in
North America of Cartistem for cartilage
regeneration—the first time a cell therapy
approved by the Korean Food and Drug
Administration has entered trials in the
USA. The 12 patient study is at Rush Uni-
versity’s Hospital, Chicago, and Brigham
and Women’s Hospital, Massachusetts.
Mesoblast has been granted by the US
Patent Office Patent 8,367,405 (isolation
of adult multipotential cells by tissue
nonspecific alkaline phosphatase), which
confers the company with exclusive rights
through March 2029 to compositions of
matter covering its current products.
Claims include a method of enriching for
adult STRO-1+ multipotential cells.
NeoStem was ranked number one in
the Tri-State region and number seven
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Fast 500.
Neuralstem received FDA approval for a
phase 1 trial in chronic thoracic spinal
cord injury with an American Spinal Injury
Association ‘‘A’’ level of impairment (com-
plete paralysis). Eight patients will receive
six injections in/around the injury. Half the
patients will receive 100,000 cells per in-
jection, and if safe and tolerated, the
dose will be ramped up to 200,000.
NewLink Genetics reported phase 1
dose escalation data for HyperAcute
prostate cancer immunotherapy (pub-
lished in the Journal of Immunotherapy).
Eight patients received 12 intradermal
vaccinations at doses ranging from 30–
500M cells. The study demonstrated
safety and evidence of vaccine-induced
immunologic responses in patients, sug-
gesting the potential for a larger study.
Northwest Biotherapeutics Chairman
and CEO Linda Powers rang Nasdaq’s
opening bell to celebrate the company’s
uplisting to the Nasdaq Capital Market.
The company completed major related
financial accomplishments to strengthen
their balance sheet by removing over
$35M of debt and closing on $14M in
new equity investment.
Osiris Therapeutics established its own
direct sales force for Grafix, a 3D cellular
matrix for serious wounds. Osiris had
earlier (May 2012) announced that it
had received transitional passthrough
status from the Center for Medicare &
Medicaid Services, with C-Codes being
designated for Grafix, thus facilitating
reimbursement when used in Medicare
patients.
Pharmicell will merge with its wholly
owned subsidiary, ID Biochem (Ulsan,
Korea), to improve synergy between
the two companies. ID Biochem is a pro-
ducer of nucleosides (used for molecular
diagnostics and gene therapy), methoxy
polyethylene glycol (mPEG) for pharma-
ceuticals, and drug intermediates. It sup-
plies mPEG to multinationals such as
Merck.
Pluristem Therapeutics’ licensee,
United Therapeutics (Silver Spring, MD,
USA), plans phase 1 studies using Pluri-
stem’s PLacental eXpanded (PLX-PAD)cells in pulmonary arterial hypertension
(PAH). Under the licensing agreement,
United Therapeutics will develop, market,
and sell PLX-PAD cells for PAH. Pluristem
received a $7M upfront payment, plus
potentially up to $48M in milestone
installments.
Prima BioMed announced that the
Saxony Development Bank (Dresden,
Germany) approved a V3.8M ($5M)
grant to support CVac development. The
award will cofund phase 2 clinical trials
in three new cancer indications and co-
fund several manufacturing optimization
programs to improve the efficiency and
commercial scale-up of production of
their cancer cell vaccine.
StemCells will receive $19M from
CIRM to help fund an IND application for
Alzheimer’s disease. The funding, in the
form of a forgivable loan, was awarded
under CIRM’s Disease Team Therapy
Development Award program, for pre-
clinical development and IND-enabling
activities.
TiGenix has obtained from the Spanish
health authorities national reimbursement
for its cartilage therapy ChondroCelect.
Spain is the second country in Europe to
provide national reimbursement for Chon-
droCelect; the first was the Netherlands in
June 2012. TiGenix continues to work on
obtaining national reimbursement in other
European countries.
Summary of Q4 2012 and Q1 2013
Activity
Overall the major news from the CTI
companies is very positive, with strong
progress being made in an assortment
of clinical indications, many for significant
unmet medical needs. The newCTI repre-
sents the start of an ongoing process and
will build over time. The BTK andNBIwere
established in 1991 and 1993, respec-
tively, and have shown the most signifi-
cant overall gains from 2009 onward. In
comparison, the cell therapy sector is still
very early in its development cycle, and
therefore has real potential for major
growth. We will regularly update and
analyze the CTI so it can be used as a per-
formance indicator for the global cell ther-
apy sector.Cell Stem CeSUPPLEMENTAL INFORMATION
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